RESUMO
Indications, contraindications, mortality and complication rates in patients undergoing percutaneous coronary interventions (PCI) are discussed in age-related aspects especially devoted to elderly. Own results of over 10-year-long experience (1998-2008) in interventional cardiology (coronary angiography, percutaneous coronary transluminal angioplasty, stenting) with 192 patients over 75 years of age (from 75 to 93 y. o.) suffering stable, unstable angina or myocardial infarction analyzed in topics of outcomes and perioperative pharmacotherapy. Special aspects of gero-pharmacotherapy based on retrospective analysis of used drugs made it possible to formulate algorithm of intraoperative hypotensive therapy and the six principles of pharmacotherapy in elderly undergoing PCI: 1) do not withdraw the previous therapy until the procedure (except warfarin); 2) therapy individualization due to concomitant diseases; 3) dosage titration starting with of common doses; 4) overwhelming pain control; 5) short acting, having antidotes drugs are preferable just as 6) geroprotective preparations. According to detailed analysis of in-hospital outcomes coronary interventions in elderly are safe enough and may be enough successful.
Assuntos
Angioplastia Coronária com Balão , Anti-Hipertensivos/uso terapêutico , Fatores Etários , Idoso , Idoso de 80 Anos ou mais , Algoritmos , Angina Instável/terapia , Angioplastia Coronária com Balão/efeitos adversos , Angioplastia Coronária com Balão/mortalidade , Anti-Hipertensivos/administração & dosagem , Contraindicações , Angiografia Coronária , Humanos , Pessoa de Meia-Idade , Infarto do Miocárdio/terapia , Avaliação de Resultados em Cuidados de Saúde , Estudos Retrospectivos , Fatores de Risco , Segurança , StentsRESUMO
Thymogen, a new immunomodulating drug made in this country, was used in combined therapy of 46 patients with acute endomyometritis, exacerbations of chronic salpingo-oophoritis, purulent tubo-ovarian formations. Thymogen therapy was conducive to normalization of lymphocyte counts, absolute counts of T and B lymphocytes, increase of T lymphocyte functional activity. The drug is characterized by a desensitizing effect and induces no complications. Marked clinical effect recommends the immunomodulator thymogen for combined therapy of patients with inflammatory diseases of the uterus and its appendages.
